Article Text

Download PDFPDF
Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC
  1. G B Frisoni1,
  2. P h Scheltens2,
  3. S Galluzzi1,
  4. F M Nobili3,
  5. N C Fox4,
  6. P H Robert5,
  7. H Soininen6,
  8. L-O Wahlund7,
  9. G Waldemar8,
  10. E Salmon9
  1. 1Laboratory of Epidemiology & Neuroimaging, IRCCS San Giovanni di Dio-FBF, Brescia, Italy
  2. 2Alzheimer Center, Department of Cognitive Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
  3. 3Division of Clinical Neurophysiology, Department of Internal Medicine, University of Genoa, Italy
  4. 4Dementia Research Group, Department of Clinical Neurology, Institute of Neurology, University College London, London, UK
  5. 5Centre Memoire, Unite d’Evaluation des Cognitions, Hopital Pasteur, Centre Hospitalier Universitaire de Nice, France
  6. 6Department of Neurology, Kuopio University Hospital, Kuopio, Finland
  7. 7Department of Clinical Neuroscience, NEUROTEC, Karolinska Institutet at Huddinge University Hospital, Huddinge, Sweden
  8. 8Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark
  9. 9Department of Neurology and Cyclotron Research Centre, University of Liege, Liege, Belgium
  1. Correspondence to:
 Dr G B Frisoni
 Laboratory of Epidemiology & Neuroimaging, IRCCS San Giovanni di Dio-FBF, via Pilastroni 4, 25125 Brescia, Italy; paperscentroalzheimer.it

Abstract

Neuroimaging is a mainstay in the differential diagnosis of patients with cognitive impairment. The often equivocal clinical pictures, the prognostic uncertainty of the earliest stages of mild cognitive impairment, and the subtle brain changes mean that neuroimaging techniques are of potentially great incremental diagnostic value. A number of methods, ranging from very simple subjective visual ratings to highly sophisticated computerised tools, have been developed, which allow rating of structural and functional brain changes. The choice of the method is not obvious, and current guidelines provide no indications on which tools should be preferred. In this paper, we give indications for tools with demonstrated accuracy for detecting regional atrophy, cerebrovascular disease, and regional brain function, and discuss these according to increasing technological complexity, ranging from those with high feasibility that can be used at the patient’s bedside to highly technological ones that require trained personnel and specific hardware and software.

  • imaging
  • cognitive impairment
  • Alzheimer’s disease
  • atrophy
  • cerebrovascular disease
  • rating scales
  • AD, Alzheimer’s disease
  • ARWMC, Age Related White Matter Changes
  • CT, computed tomography
  • MCI, mild cognitive impairment
  • MR, magnetic resonance
  • MTL, medial temporal lobe
  • MMS, Mini Mental State
  • PET, positron emission tomography
  • SPET, single photon emission tomography

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interest: none declared